Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2013

View Archived Issues

ADAM10: potential target and genetic marker for late-onset AD

Discovery of a broad-genotype inhibitor of HCV replication

AllaChem completes phase I study of AV-4025

Hasselt University and Inova Diagnostics collaborate on biomarkers for RA

AstraZeneca selects miRNA oncology target under alliance with Regulus Therapeutics

STADA in-licenses approved biosimilar from Apotex

Santaris resumes full ownership of LNA programs licensed to Enzon

BELLUS Health and AmorChem sign co-development agreement for AL amyloidosis

BioTime discloses interim results from safety study of Renevia

Phase I/II trial of vosaroxin in myelodysplastic syndrome begins

Sophiris begins dosing in PLUS-1 phase III trial of PRX-302

Etanercept biosimilar product meets primary endpoint in pivotal study

Updated clinical data on nintedanib reported

Crown Bioscience describes patient-derived xenografts for testing CBI-3103

Bristol-Myers Squibb reports developments of third quarter 2013

University of South Florida discloses new myricanol derivatives

French team presents novel diagnostics for Alzheimer's disease

Novartis reports progress during third quarter 2013

Polish researchers patent new bacterial efflux pump inhibitors

Researchers at Apac Pharmaceutical synthesize novel agents for arthritis

Pharmacodynamic activity seen for AMG-811 in patients with SLE

Janssen Pharmaceutica divulges new CCR2 receptor antagonists

Stemline Therapeutics to accelerate development of SL-401 in hematologic cancers

Cara Therapeutics reports results from phase II trial of CR-845

Novel osteoporosis mouse models carry human RANKL gene

OncoMed Pharmaceuticals begins phase Ib trial of vantictumab with paclitaxel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...